SPRINT trial (nifedipine after MI)
The SPRINT trial had to be prematurely terminated after recruiting 1358 patients because the use of nifedipine increased mortality following acute myocardial infarction.
Patients were randomised within 48 hr of a myocardial infarction to:
- nifedipine 60 mg/day
- placebo
Mortality at 6 months in the placebo group was 13.3% compared to 15.4% in the nifedipine group.
The conclusion is that routine use of calcium channel blockers following myocardial infarction should be avoided.
Reference:
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.